OIG levies largest fine ever for corporate integrity agreement violation

Kindred Health Care, the largest provider of post-acute care services in the U.S., has paid a $3 million penalty for failing to comply with a corporate integrity agreement (CIA) with HHS’s Office of the Inspector General (OIG).

It’s the largest fine ever for a CIA violation, which OIG said was due to the company’s failure to correct improper billing practices in the fourth year of a five-year agreement.

“This penalty should send a signal to providers that failure to implement these requirements will have serious consequences," said HHS Inspector General Daniel Levinson. “We will continue to closely monitor Kindred's compliance with the CIA.”

The specific violation in this case involved Kindred billing Medicare for hospice care for patients who weren’t eligible for such services at the highest level and most highly paid category. OIG said due to these findings, Kindred closed 18 sites it labeled as “underperforming” since March 2015.

The overpayment issues were uncovered by audits required by Kindred’s CIA in 2013, 2014 and 2015. For 2016, OIG said the company “took significant corrective actions, including upgrading internal audits and investigations and tracking resolutions of identified issues.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.